

Malaysia Results Review

12 August 2022

Financial Services | Banks

Buy (Maintained)

Target Price (Return): MYR1.92 (+16%) Price (Market Cap): MYR1.66 (USD273m) ESG score: 3.10 (out of 4)

Avg Daily Turnover (MYR/USD)



0.34m/0.08m

Analyst

fiona.leong@rhbgroup.com



	YTD	1m	3m	6m	12m
Absolute	(16.1)	1.2	(7.8)	(7.3)	16.2
Relative	(12.1)	(4.4)	(4.6)	(2.6)	16.1
52-wk Price lo	w/high (MYF	?)		1.43	- 2.06

RCE Capital Ordinary (RCE MK) Relative to FTSE Bursa Malaysia KLCI Index (RHS) 155 148 140 133 125 118 110 103

Source: Bloomberg

Fiona Leong +603 9280 8886



Share Performance (%)

Overall ESG Score: 3.10 (out of 4)

The group maintains transparent and detailed disclosures of its Scope 1 and Scope 2 emissions, which has recorded a decent reduction of 3% between FY22 (Mar) and FY20. It also fosters a culture of green volunteerism through its Green Warriorz Team, and designated e-waste containers on office floors to encourage the proper disposal of e-waste such as unused gadgets and batteries.

S: GOOD

RCE outsources the auditing of its IT systems to ensure that competency standards are met. The group, in collaboration with Yayasan Azman Hashim, also provides study grants and scholarships to deserving underprivileged students to pursue chartered accountancy certifications. To date, MYR524,000 has been distributed under the programme.

G: EXCELLENT

The Board comprises nine non-executive directors, five of whom are independent directors. Board members have a maximum allowed tenure of nine years, to facilitate Board refreshment. However, in FY22, there was a one-off incident of non-compliance in relation to a late payment of service tax due to administrative delay, but that has since been resolved.

Small cap stocks are defined as companies with a market capitalization of less than USD0.5bn.

RCE Capital (RCE MK)

1QFY23: Weighed Down By Higher Provisions

• Stay BUY, new MYR1.92 TP from MYR2.00, 16% upside with c.5% FY23F (Mar) yield. RCE Capital's 1QFY23 results missed expectations, mainly due to the conservative impairment of accounts. We expect provisions to normalise in the quarters ahead, as asset quality stabilises and recovery efforts are being stepped up. This, coupled with sustained financing demand, point to better earnings ahead. Contrary to concerns, we believe NIM compression would be manageable, given mitigation efforts by management.

- 1QFY23 results missed estimates. 1QFY23 net profit of MYR32.2m (+2% QoQ, -9% YoY), accounted for c.24% of our and consensus FY23F earnings. The YoY decline was mainly due to the full impairment of accounts that dropped off from the salary deduction scheme. PIOP grew by a modest 1.5% YoY, as lower income from early settlements led to a 5.5% YoY drop in net fund-based income, which offset the 27% YoY growth in other income. 1QFY23 ROAE was 14.8% vs 14.7% in 4QFY22.
- Asset quality. Impairment allowances spiked to MYR8.2m in 1QFY23 (4QFY22: MYR5.9m), matching the 4QFY20 peak seen during the COVID-19 pandemic. Management attributed this to the conservative full provisioning of exposures to borrowers that had left the civil service. There were noticeable resignations and early retirements within the academic and healthcare sectors. GILs rose 6.5% QoQ, lifting the GIL ratio to 4.0% vs 3.8% 4QFY23. Efforts are being made to recover the outstanding balances, which would result in write-backs, if successful. Management remains vigilant on asset quality, notwithstanding the improvement seen in July.
- Demand for financing still strong. Gross financing grew 1.4% QoQ (FY22: +1.8% YoY), helped by the economic reopening. Management believes growth is sustainable, given the strong momentum in financing applications. RCE has also launched some campaigns to capture the lending opportunity. We have pencilled in loan growth of 4% for FY23F.
- Working to manage NIM pressures. With all of RCE's financing receivables on fixed rates, against 71.5% of its financing liabilities being on fixed rates as well, the rising interest rate environment would have a negative impact on NIM. To mitigate the NIM pressures, RCE is focusing on higher-profit rate products to boost asset yields, while the utilisation of floating rate revolving credits has helped to lower funding costs. These measures should help keep NIM compression manageable.
- Earnings and TP. With 1QFY23 PIOP within our expectations and credit cost likely to normalise, we make no changes to our FY23-25F earnings, for now. Our TP drops to MYR1.92 (from MYR2.00), as we refreshed our GGM assumptions for heighten macroeconomic risks. Our TP also incorporates a 2% premium to our intrinsic value for its ESG score of 3.10, based on our inhouse proprietary methodology.
- The downside risks to our call includes: i) Higher-than-expected credit cost, and ii) weaker-than-expected financing growth and net financing margins.

Forecasts and Valuation	Mar-21	Mar-22	Mar-23F	Mar-24F	Mar-25F
Reported net profit (MYRm)	125	133	136	139	147
Net profit growth (%)	12.7	6.9	2.3	2.0	5.6
Recurring net profit (MYRm)	125	133	136	139	147
Recurring EPS (MYR)	0.18	0.18	0.19	0.19	0.20
BVPS (MYR)	1.13	1.19	1.15	1.11	1.06
DPS (MYR)	0.07	0.07	0.08	0.09	0.09
Recurring P/E (x)	9.13	9.12	8.92	8.74	8.28
P/B (x)	1.47	1.39	1.44	1.50	1.57
Dividend Yield (%)	4.3	4.5	4.8	5.1	5.4
Return on average equity (%)	17.2	16.2	15.9	16.8	18.5

Source: Company data, RHB

P/B (x)

Dividend Yield (%)

1.5

5.1

1.6

5.4

Financial Exhibits

Asia Malaysia Financial Services RCE Capital RCE MK Buy

Valuation basis

Our GGM assumptions are:

- i. CoE of 11.8%;
- ii. ROE of 17.0%;
- iii. 3.5% long-term growth rate.

Key drivers

Our FY23 forecasts are most sensitive to changes in:

- i. Financing margins;
- ii. Impairment allowances;
- iii. Growth in receivables.

Key risks

The downside risks include:

- i. Higher-than-expected credit cost;
- ii. Weaker-than-expected financing growth;
- iii. Weaker-than-expect net financing margin.

Company Profile

RCE Capital provides general financing services to civil servants – repayments are done via direct salary deductions. Its wholly-owned EXP Payment unit offers payroll collection management services for government departments under the purview of the Accountant General's Department.

Financial summary (MYR)	Mar-21	Mar-22	Mar-23F	Mar-24F	Mar-25F
EPS	0.18	0.18	0.19	0.19	0.20
Recurring EPS	0.18	0.18	0.19	0.19	0.20
DPS	0.07	0.07	0.08	0.09	0.09
BVPS	1.13	1.19	1.15	1.11	1.06
Valuation metrics	Mar-21	Mar-22	Mar-23F	Mar-24F	Mar-25F
Recurring P/F (x)	9 13	9 12	8 92	8 74	8.28

1.4

4.5

1.4

4.8

1.5

4.3

Income statement (MYRm)	Mar-21	Mar-22	Mar-23F	Mar-24F	Mar-25F
Interest income	273	275	288	294	309
Interest expense	(81)	(80)	(88)	(91)	(95)
Net interest income	192	194	200	203	215
Non interest income	39	45	52	55	57
Total operating income	232	239	252	258	272
Overheads	(49)	(51)	(53)	(55)	(57)
Pre-provision operating profit	183	189	200	203	215
Loan impairment allowances	(16)	(12)	(17)	(17)	(18)
Pre-tax profit	167	177	183	187	197
Taxation	(43)	(44)	(47)	(48)	(50)
Reported net profit	125	133	136	139	147
Recurring net profit	125	133	136	139	147

Profitability ratios	Mar-21	Mar-22	Mar-23F	Mar-24F	Mar-25F
Return on average assets (%)	5.1	5.1	5.0	5.0	5.3
Return on average equity (%)	17.2	16.2	15.9	16.8	18.5
Return on IEAs (%)	11.7	10.9	11.2	11.2	11.3
Cost of funds (%)	4.8	4.6	4.8	4.8	4.9
Net interest spread (%)	7.0	6.2	6.4	6.4	6.4
Net interest margin (%)	8.3	7.7	7.8	7.8	7.8
Non-interest income / total income (%)	17.0	18.9	20.6	21.2	21.0
Cost to income ratio (%)	21.1	21.1	20.9	21.3	21.0
Credit cost (bps)	85.1	62.0	87.7	82.6	84.1

Balance sheet (MYRm)	Mar-21	Mar-22	Mar-23F	Mar-24F	Mar-25F
Total gross loans	1,845	1,879	1,954	2,052	2,155
Other interest earning assets	625	702	604	631	660
Total gross IEAs	2,471	2,581	2,558	2,684	2,815
Total provisions	(124)	(115)	(120)	(125)	(131)
Net loans to customers	1,721	1,764	1,834	1,927	2,023
Total net IEAs	2,346	2,466	2,438	2,558	2,684
Total non-IEAs	144	260	313	216	112
Total assets	2,491	2,725	2,751	2,774	2,796
Other interest-bearing liabilities	1,671	1,804	1,858	1,914	1,971
Total IBLs	1,671	1,804	1,858	1,914	1,971
Total non-IBLs	46	49	49	50	50
Total liabilities	1,717	1,853	1,907	1,963	2,022
Share capital	188	201	213	226	239
Shareholders' equity	774	872	844	811	774

Asset quality and capital	Mar-21	Mar-22	Mar-23F	Mar-24F	Mar-25F
Reported NPLs / gross cust loans (%)	4.0	3.8	3.8	3.8	3.8
Total provisions / reported NPLs (%)	168.4	162.8	161.7	0.0	0.0

Source: Company data, RHB



Results At a Glance

Figure 1: RCE - 1QFY23 results summary

FYE Mar (MYRm)	1QFY22	4QFY22	1QFY23	% QoQ	% YoY	Comments – 1QFY23 vs 1QFY22
Net fund based income	51.7	50.3	48.8	(2.8)	(5.5)	Down YoY, mainly due to lower income from early
Net fund based income	51.7	50.5	40.0	(2.0)	(5.5)	settlements.
Financing income	71.6	70.4	69.2	(1.6)	(3.3)	
Financing expense	(19.9)	(20.1)	(20.4)	1.4	2.5	
Non-fund based income	11.1	10.1	14.0	39.4	27.0	Higher placement fees from cash balances with banks.
Non-fund based inc/Total income (%)	17.6	16.7	22.3			
Operating income	62.7	60.3	62.9	4.2	0.2	
Overheads	(12.4)	(13.1)	(11.8)	(9.6)	(4.9)	Lower YoY, on the\ reduction in fees for financing facilities.
CIR (%)	19.8	21.6	18.8			
PIOP	50.3	47.3	51.1	8.0	1.5	
Impairment on financings	(3.1)	(5.9)	(8.2)	39.9	>100	Spike in provisions due to full provisions for accounts that have dropped off the salary deduction scheme.
Credit cost	67	125	173			
Pre-tax profit	47.3	41.4	42.9	3.5	(9.2)	
Tax	(11.9)	(9.9)	(10.7)			
ETR (%)	25.1	23.9	24.9			
Net earnings	35.4	31.5	32.2	2.2	(8.9)	
Gross financing	1,853.4	1,879.2	1,904.7	1.4	2.8	
Total borrowings	1,718.2	1,804.0	1,847.0	2.4	7.5	
Gross impaired financing	(123.4)	(115.1)	(118.3)	2.7	(4.2)	
Total assets	2,576.7	2,725.3	2,767.3	1.5	7.4	
Shareholders' funds	787.1	872.1	875.0	0.3	11.2	
ROAA	5.6%	4.7%	4.7%			
ROAE	18.1%	14.7%	14.8%			
GIL ratio	4.0%	3.8%	4.0%			

Source: Company data, RHB

Valuation and TP

We lower our TP to MYR1.92 from MYR2.00 after refreshing our GGM assumptions – namely a higher equity risk premium, given the heightened macroeconomic headwinds. The TP includes an ESG premium of 2% (unchanged), based on RHB's in-house methodology.

Our intrinsic value of MYR1.88 is based on a GGM-derived P/BV of 1.63x.

Figure 2: RCE - GGM valuation with ESG overlay

Cost of equity (COE) computation:		Sustainable ROE (%)	17.0
Risk free rate (%)	4.0	COE (%)	11.8
Equity premium (%)	6.8	Long-term growth (g)	3.5
Beta (x)	1.2	Implied P/BV (x)	1.63
Cost of equity - CAPM (%)	11.8	BVPS - 12mth forward	MYR1.16
		Intrinsic value	MYR1.88
ESG premium/(discount) (%)	2.0	ESG premium/(discount)	MYR0.04
		TP (rounded)	MYR1.92

Source: Company data, RHB



Recommendation Chart




Source: RHB, Bloomberg

Date	Recommendation	Target Price	Price
2022-05-31	Buy	2.00	1.76
2022-02-25	Buy	1.90	1.69
2021-11-10	Neutral	3.90	2.02
2021-08-12	Buy	3.20	1.43
2021-05-26	Buy	3.20	1.43
2021-02-09	Buy	3.00	1.32
2020-12-08	Buy	2.80	1.29
2020-08-18	Buy	2.50	1.02
2020-07-06	Buy	2.50	1.01
2020-06-16	Buy	2.20	0.95
2020-03-15	Buy	2.10	0.79
2020-02-19	Buy	2.20	0.93
2020-02-19	Buy	2.20	0.93
2020-01-10	Buy	2.10	0.90
2019-08-16	Not Rated	na	0.84

Source: RHB, Bloomberg

ESG Rating History



RHB Guide to Investment Ratings

Buy: Share price may exceed 10% over the next 12 months

Trading Buy: Share price may exceed 15% over the next 3 months, however longer-

term outlook remains uncertain

Neutral: Share price may fall within the range of +/- 10% over the next

12 months

Take Profit: Target price has been attained. Look to accumulate at lower levels Sell: Share price may fall by more than 10% over the next 12 months

Not Rated: Stock is not within regular research coverage

Investment Research Disclaimers

RHB has issued this report for information purposes only. This report is intended for circulation amongst RHB and its affiliates' clients generally or such persons as may be deemed eligible by RHB to receive this report and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. This report is not intended, and should not under any circumstances be construed as, an offer or a solicitation of an offer to buy or sell the securities referred to herein or any related financial instruments.

This report may further consist of, whether in whole or in part, summaries, research, compilations, extracts or analysis that has been prepared by RHB's strategic, joint venture and/or business partners. No representation or warranty (express or implied) is given as to the accuracy or completeness of such information and accordingly investors should make their own informed decisions before relying on the same.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to the applicable laws or regulations. By accepting this report, the recipient hereof (i) represents and warrants that it is lawfully able to receive this document under the laws and regulations of the jurisdiction in which it is located or other applicable laws and (ii) acknowledges and agrees to be bound by the limitations contained herein. Any failure to comply with these limitations may constitute a violation of applicable laws.

All the information contained herein is based upon publicly available information and has been obtained from sources that RHB believes to be reliable and correct at the time of issue of this report. However, such sources have not been independently verified by RHB and/or its affiliates and this report does not purport to contain all information that a prospective investor may require. The opinions expressed herein are RHB's present opinions only and are subject to change without prior notice. RHB is not under any obligation to update or keep current the information and opinions expressed herein or to provide the recipient with access to any additional information. Consequently, RHB does not guarantee, represent or warrant, expressly or impliedly, as to the adequacy, accuracy, reliability, fairness or completeness of the information and opinion contained in this report. Neither RHB (including its officers, directors, associates, connected parties, and/or employees) nor does any of its agents accept any liability for any direct, indirect or consequential losses, loss of profits and/or damages that may arise from the use or reliance of this research report and/or further communications given in relation to this report. Any such responsibility or liability is hereby expressly disclaimed.

Whilst every effort is made to ensure that statement of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable and must not be construed as a representation that the matters referred to therein will occur. Different assumptions by RHB or any other source may yield substantially different results and recommendations contained on one type of research product may differ from recommendations contained in other types of research. The performance of currencies may affect the value of, or income from, the securities or any other financial instruments referenced in this report. Holders of depositary receipts backed by the securities discussed in this report assume currency risk. Past performance is not a guide to future performance. Income from investments may fluctuate. The price or value of the investments to which this report relates, either directly or indirectly, may fall or rise against the interest of investors.

This report may contain comments, estimates, projections, forecasts and expressions of opinion relating to macroeconomic research published by RHB economists of which should not be considered as investment ratings/advice and/or a recommendation by such economists on any securities discussed in this report.

This report does not purport to be comprehensive or to contain all the information that a prospective investor may need in order to make an investment decision. The recipient of this report is making its own independent assessment and decisions regarding any securities or financial instruments referenced herein. Any investment discussed or recommended in this report may be unsuitable for an investor depending on the investor's specific investment objectives and financial position. The material in this report is general information intended for recipients who understand the risks of investing in financial instruments. This report does not take into account whether an investment or course of action and any associated risks are suitable for the recipient. Any recommendations contained in this report must therefore not be relied upon as investment advice based on the recipient's personal circumstances. Investors should make their own independent evaluation of the information contained herein, consider their own investment objective, financial situation and particular needs and seek their own financial, business, legal, tax and other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this report.

This report may contain forward-looking statements which are often but not always identified by the use of words such as "believe", "estimate", "intend" and "expect" and statements that an event or result "may", "will" or "might" occur or be achieved and other similar expressions. Such forward-looking statements are based on assumptions made and information currently available to RHB and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement to be materially different from any future results, performance or achievement, expressed or implied by such forward-looking statements. Caution should be taken with respect to such statements and recipients of this report should not place undue reliance on any such forward-looking statements. RHB expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances after the date of this publication or to reflect the occurrence of unanticipated events.

The use of any website to access this report electronically is done at the recipient's own risk, and it is the recipient's sole responsibility to take precautions to ensure that it is free from viruses or other items of a destructive nature. This report may also provide the addresses of, or contain hyperlinks to, websites. RHB takes no responsibility for the content contained therein. Such addresses or hyperlinks (including addresses or hyperlinks to RHB own website material) are provided solely for the recipient's convenience. The information and the content of the linked site do not in any way form part of this report. Accessing such website or following such link through the report or RHB website shall be at the recipient's own risk.

This report may contain information obtained from third parties. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content.

The research analysts responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously. The research analysts that authored this report are precluded by RHB in all circumstances from trading in the securities or other financial instruments referenced in the report, or from having an interest in the company(ies) that they cover.

The contents of this report is strictly confidential and may not be copied, reproduced, published, distributed, transmitted or passed, in whole or in part, to any other person without the prior express written consent of RHB and/or its affiliates. This report has been delivered to RHB and its affiliates' clients for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above. By electing to view or accepting a copy of this report, the recipients have agreed that they will not print, copy, videotape, record, hyperlink, download, or otherwise attempt to reproduce or re-transmit (in any form including hard copy or electronic distribution format) the contents of this report. RHB and/or its affiliates accepts no liability whatsoever for the actions of third parties in this respect.

The contents of this report are subject to copyright. Please refer to Restrictions on Distribution below for information regarding the distributors of this report. Recipients must not reproduce or disseminate any content or findings of this report without the express permission of RHB and the distributors.

The securities mentioned in this publication may not be eligible for sale in some states or countries or certain categories of investors. The recipient of this report should have regard to the laws of the recipient's place of domicile when contemplating transactions in the securities or other financial instruments referred to herein. The securities discussed in this report may not have been registered in such jurisdiction. Without prejudice to the foregoing, the recipient is to note that additional disclaimers, warnings or qualifications may apply based on geographical location of the person or entity receiving this report.

The term "RHB" shall denote, where appropriate, the relevant entity distributing or disseminating the report in the particular jurisdiction referenced below, or, in every other case, RHB Investment Bank Berhad and its affiliates, subsidiaries and related companies.

RESTRICTIONS ON DISTRIBUTION

Malaysia

This report is issued and distributed in Malaysia by RHB Investment Bank Berhad ("RHBIB"). The views and opinions in this report are our own as of the date hereof and is subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. RHBIB has no obligation to update its opinion or the information in this report.

Thailand

This report is issued and distributed in the Kingdom of Thailand by RHB Securities (Thailand) PCL, a licensed securities company that is authorised by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is a



member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. RHB Securities (Thailand) PCL does not endorse, confirm nor certify the result of the Corporate Governance Report of Thai Listed Companies.

This report is issued and distributed in Indonesia by PT RHB Sekuritas Indonesia. This research does not constitute an offering document and it should not be construed as an offer of securities in Indonesia. Any securities offered or sold, directly or indirectly, in Indonesia or to any Indonesian citizen or corporation (wherever located) or to any Indonesian resident in a manner which constitutes a public offering under Indonesian laws and regulations must comply with the prevailing Indonesian laws and regulations.

This report is issued and distributed in Singapore by RHB Bank Berhad (through its Singapore branch) which is an exempt capital markets services entity and an exempt financial adviser regulated by the Monetary Authority of Singapore. RHB Bank Berhad (through its Singapore branch) may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, RHB Bank Berhad (through its Singapore branch) accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact RHB Bank Berhad (through its Singapore branch) in respect of any matter arising from or in connection with the report.

United States

This report was prepared by RHB is meant for distribution solely and directly to "major" U.S. institutional investors as defined under, and pursuant to, the requirements of Rule 15a-6 under the U.S. Securities and Exchange Act of 1934, as amended (the "Exchange Act") via a registered U.S. broker-dealer as appointed by RHB from time to time. Accordingly, any access to this report via Bursa Marketplace or any other Electronic Services Provider is not intended for any party other than "major" US institutional investors (via a registered U.S broker-dealer), nor shall be deemed as solicitation by RHB in any manner. RHB is not registered as a broker-dealer in the United States and currently has not appointed a U.S. broker-dealer. Additionally, RHB does not offer brokerage services to U.S. persons. Any order for the purchase or sale of all securities discussed herein must be placed with and through a registered U.S. broker-dealer as appointed by RHB from time to time as required by the Exchange Act Rule 15a-6. For avoidance of doubt, RHB reiterates that it has not appointed any U.S. broker-dealer during the issuance of this report. This report is confidential and not intended for distribution to, or use by, persons other than the recipient and its employees, agents and advisors, as applicable. Additionally, where research is distributed via Electronic Service Provider, the analysts whose names appear in this report are not registered or qualified as research analysts in the United States and are not associated persons of any registered U.S. broker-dealer as appointed by RHB from time to time and therefore may not be subject to any applicable restrictions under Financial Industry Regulatory Authority ("FINRA") rules on communications with a subject company, public appearances and personal trading. Investing in any non-U.S. securities or related financial instruments discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in the United States. The financial instruments discussed in this report may not be suitable for all investors. Transactions in foreign markets may be subject to regulations that differ from or offer less protection than those in the United States.

DISCLOSURE OF CONFLICTS OF INTEREST

RHB Investment Bank Berhad, its subsidiaries (including its regional offices) and associated companies, ("RHBIB Group") form a diversified financial group, undertaking various investment banking activities which include, amongst others, underwriting, securities trading, market making and corporate finance advisory.

As a result of the same, in the ordinary course of its business, any member of the RHBIB Group, may, from time to time, have business relationships with, hold any positions in the securities and/or capital market products (including but not limited to shares, warrants, and/or derivatives), trade or otherwise effect transactions for its own account or the account of its customers or perform and/or solicit investment, advisory or other services from any of the subject company(ies) covered in this research report.

While the RHBIB Group will ensure that there are sufficient information barriers and internal controls in place where necessary, to prevent/manage any conflicts of interest to ensure the independence of this report, investors should also be aware that such conflict of interest may exist in view of the investment banking activities undertaken by the RHBIB Group as mentioned above and should exercise their own judgement before making any investment decisions.

In Singapore, investment research activities are conducted under RHB Bank Berhad (through its Singapore branch), and the disclaimers above similarly apply.

Save as disclosed in the following link RHB Research conflict disclosures – Aug 2022 and to the best of our knowledge, RHBIB hereby declares that:

- RHBIB does not have a financial interest in the securities or other capital market products of the subject company(ies) covered in this report.
 RHBIB is not a market maker in the securities or capital market products of the
- subject company(ies) covered in this report.
- None of RHBIB's staff or associated person serve as a director or board member* of the subject company(ies) covered in this report *For the avoidance of doubt, the confirmation is only limited to the staff of research
- RHBIB did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
- RHBIB did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report.

- Save as disclosed in the following link RHB Research conflict disclosures Aug 2022 and to the best of our knowledge, RHB Securities (Thailand) PCL hereby declares that:
 RHB Securities (Thailand) PCL does not have a financial interest in the securities or other capital market products of the subject company(ies) covered in this report.
 RHB Securities (Thailand) PCL is not a market maker in the securities or capital
- market products of the subject company(ies) covered in this report.
- None of RHB Securities (Thailand) PCL's staff or associated person serve as a director or board member* of the subject company(ies) covered in this report
- *For the avoidance of doubt, the confirmation is only limited to the staff of research department
- RHB Securities (Thailand) PCL did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
- RHB Securities (Thailand) PCL did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report.

Indonesia

Save as disclosed in the following link RHB Research conflict disclosures – Aug 2022 and to the best of our knowledge, PT RHB Sekuritas Indonesia hereby declares that:

- PT RHB Sekuritas Indonesia and its investment analysts, does not have any interest in the securities of the subject company(ies) covered in this report. For the avoidance of doubt, interest in securities include the following:
 - a) Holding directly or indirectly, individually or jointly own/hold securities or entitled for dividends, interest or proceeds from the sale or exercise of the
 - subject company's securities covered in this report*;
 Being bound by an agreement to purchase securities or has the right to transfer the securities or has the right to pre subscribe the securities*
 - Being bound or required to buy the remaining securities that are not subscribed/placed out pursuant to an Initial Public Offering*.
 - Managing or jointly with other parties managing such parties as referred to in (a), (b) or (c) above.
- PT RHB Sekuritas Indonesia is not a market maker in the securities or capital market products of the subject company(ies) covered in this report.

 None of PT RHB Sekuritas Indonesia's staff** or associated person serve as a
- director or board member* of the subject company(ies) covered in this report.
- PT RHB Sekuritas Indonesia did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
- PT RHB Sekuritas Indonesia** did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report:

Notes:

*The overall disclosure is limited to information pertaining to PT RHB Sekuritas Indonesia only.

*The disclosure is limited to Research staff of PT RHB Sekuritas Indonesia only.

Singapore

Save as disclosed in the following link RHB Research conflict disclosures – Aug 2022 and to the best of our knowledge, the Singapore Research department of RHB Bank Berhad (through its Singapore branch) hereby declares that:

- RHB Bank Berhad, its subsidiaries and/or associated companies do not make a market in any issuer covered by the Singapore research analysts in this report.
- RHB Bank Berhad, its subsidiaries and/or its associated companies and its analysts do not have a financial interest (including a shareholding of 1% or more) in the issuer covered by the Singapore research analysts in this report.
- 3. RHB Bank Berhad's Singapore research staff or connected persons do not serve on the board or trustee positions of the issuer covered by the Singapore research analysts in this report.
- RHB Bank Berhad, its subsidiaries and/or its associated companies do not have and have not within the last 12 months had any corporate finance advisory relationship with the issuer covered by the Singapore research analysts in this report or any other relationship that may create a potential conflict of interest.
- 5. RHB Bank Berhad's Singapore research analysts, or person associated or connected to it do not have any interest in the acquisition or disposal of, the securities, specified securities based derivatives contracts or units in a collective investment scheme covered by the Singapore research analysts in this report.
- RHB Bank Berhad's Singapore research analysts do not receive any compensation or benefit in connection with the production of this research report or recommendation on the issuer covered by the Singapore research analysts.

Analyst Certification

The analyst(s) who prepared this report, and their associates hereby, certify that:



(1) they do not have any financial interest in the securities or other capital market products of the subject companies mentioned in this report, except for:

Analyst	Company
-	=

(2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.



KUALA LUMPUR

RHB Investment Bank Bhd

Level 3A, Tower One, RHB Centre Jalan Tun Razak Kuala Lumpur 50400 Malaysia

Tel: +603 9280 8888 Fax: +603 9200 2216

BANGKOK

RHB Securities (Thailand) PCL

10th Floor, Sathorn Square Office Tower 98, North Sathorn Road, Silom Bangrak, Bangkok 10500 Thailand

Tel: +66 2088 9999 Fax:+66 2088 9799

JAKARTA

PT RHB Sekuritas Indonesia

Revenue Tower, 11th Floor, District 8 - SCBD Jl. Jendral Sudirman Kav 52-53 Jakarta 12190

Indonesia

Tel: +6221 509 39 888 Fax: +6221 509 39 777

SINGAPORE

RHB Bank Berhad (Singapore branch)

90 Cecil Street #04-00 RHB Bank Building Singapore 069531 Fax: +65 6509 0470